{"id":804458,"date":"2026-04-24T17:33:01","date_gmt":"2026-04-24T17:33:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=804458"},"modified":"2026-04-24T17:33:01","modified_gmt":"2026-04-24T17:33:01","slug":"antibody-therapeutics-market-to-reach-4790-billion-by-2028-driven-by-oncology-demand-and-biologic-innovation","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antibody-therapeutics-market-to-reach-4790-billion-by-2028-driven-by-oncology-demand-and-biologic-innovation_804458.html","title":{"rendered":"Antibody Therapeutics Market to Reach $479.0 Billion by 2028 Driven by Oncology Demand and Biologic Innovation"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777032147.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Antibody Therapeutics Market to Reach $479.0 Billion by 2028 Driven by Oncology Demand and Biologic Innovation\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777032147.jpg\" alt=\"Antibody Therapeutics Market to Reach $479.0 Billion by 2028 Driven by Oncology Demand and Biologic Innovation\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune &#038; Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) &#038; Region &#8211; Global Forecast to 2028<\/div>\n<p style=\"text-align: justify;\"><strong>According to MarketsandMarkets&trade;,<\/strong> the global <strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/antibody-therapeutics-market-178852478.html?utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">antibody therapeutics market<\/a><\/strong> is projected to grow from USD 247.3 billion in 2023 to USD 479.0 billion by 2028, registering a robust CAGR of 14.1%. This significant expansion reflects accelerating innovation in antibody engineering, increasing demand for targeted therapies, and a rapidly growing clinical pipeline. As biologics continue to redefine modern medicine, how are antibody therapeutics shaping the future of disease treatment?<\/p>\n<p style=\"text-align: justify;\"><strong>Download PDF Brochure: <a rel=\"nofollow\" name=\"www_marketsandmarkets_com_pdfdownlo\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=178852478&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=178852478<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Browse<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>313 <\/strong>Market Data Tables<\/li>\n<li><strong>51 <\/strong>Figures<\/li>\n<li><strong>306 <\/strong>Pages and in-depth TOC on<strong> &#8220;<\/strong> <strong>Antibody Therapeutics Market<\/strong> <strong><strong>&#8211; Global Forecast to 2028&rdquo;.<\/strong><\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>What is driving this remarkable market growth?<\/strong><\/p>\n<p style=\"text-align: justify;\">Continuous advancements in antibody engineering technologies are enabling the development of highly specific and effective therapies. These innovations, combined with increasing investments in research and development, are enhancing treatment outcomes across multiple disease areas, particularly in oncology and autoimmune disorders.<\/p>\n<p style=\"text-align: justify;\"><strong>Why are monoclonal antibodies leading the format segment?<\/strong><\/p>\n<p style=\"text-align: justify;\">Monoclonal antibodies (mAbs) represent the fastest-growing segment due to their high target specificity and expanding pipeline. Their ability to precisely target disease-causing cells while minimizing off-target effects has made them a cornerstone of modern therapeutics, particularly in complex and chronic conditions.<\/p>\n<p style=\"text-align: justify;\"><strong>How is oncology influencing market expansion?<\/strong><\/p>\n<p style=\"text-align: justify;\">The oncology segment is emerging as the fastest-growing disease area within the antibody therapeutics market. A strong pipeline of antibody-based cancer therapies, coupled with rising global cancer incidence, is driving significant investment and innovation in this segment. These therapies are increasingly being adopted as frontline and combination treatments, transforming cancer care paradigms.<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Pages: <a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=178852478&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=178852478<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Regional Insights:<\/strong><\/p>\n<p style=\"text-align: justify;\">What makes Europe a key growth hub? Europe represents the second-largest market for antibody therapeutics, supported by strong research infrastructure and advancements in biologics development. Countries such as Germany, the UK, and France are at the forefront of innovation, benefiting from the presence of leading pharmaceutical companies and robust regulatory frameworks that support therapeutic advancements.<\/p>\n<p style=\"text-align: justify;\"><strong>Market Insights:<\/strong><\/p>\n<p style=\"text-align: justify;\">The antibody therapeutics market is highly consolidated, with major players focusing on strategic collaborations, product innovation, and pipeline expansion. Key companies include F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson &amp; Johnson (US), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US), and Merck KGaA (Germany). These organizations are actively shaping the competitive landscape through innovation and global expansion strategies.<\/p>\n<p style=\"text-align: justify;\">As antibody therapeutics continue to revolutionize treatment across disease areas, stakeholders must align with emerging trends in biologics, precision medicine, and oncology innovation. To access detailed market insights, competitive analysis, and strategic opportunities, explore the full report today.<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=115323820&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">Monoclonal Antibody Therapeutics Market<\/a> &#8211; Global Forecast to 2029<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=153222146&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">Hematology Analyzers and Reagents Market<\/a> &#8211; Global Forecast to 2029<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=antibody-therapeutics-market-to-reach-4790-billion-by-2028-driven-by-oncology-demand-and-biologic-innovation\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/antibody-therapeutics-market-178852478.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/antibody-therapeutics-market-178852478.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=antibody-therapeutics-market-to-reach-4790-billion-by-2028-driven-by-oncology-demand-and-biologic-innovation\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune &#038; Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) &#038; Region &#8211; Global Forecast to 2028 According to MarketsandMarkets&trade;, the global antibody therapeutics market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/antibody-therapeutics-market-to-reach-4790-billion-by-2028-driven-by-oncology-demand-and-biologic-innovation_804458.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,411,404],"tags":[],"class_list":["post-804458","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/804458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=804458"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/804458\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=804458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=804458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=804458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}